美国食品药品监督管理局批准二价人乳头瘤病毒疫苗（HPV2，佳达修）用于女性，并更新了免疫实践咨询委员会（ACIP）的 HPV 疫苗接种建议。

FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP).

出版信息

MMWR Morb Mortal Wkly Rep. 2010 May 28;59(20):626-9.

PMID:20508593

Abstract

On October 16, 2009, the Food and Drug Administration (FDA) licensed bivalent human papillomavirus vaccine (HPV2; Cervarix, GlaxoSmithKline) for use in females aged 10 through 25 years. Cervarix is the second human papillomavirus (HPV) vaccine licensed for use in females in the United States. Quadrivalent HPV vaccine (HPV4; Gardasil, Merck & Co, Inc.) was licensed in 2006 for use in females aged 9 through 26 years, and the Advisory Committee on Immunization Practices (ACIP) recommended routine HPV4 vaccination of females aged 11 or 12 years, and catch-up vaccination for females aged 13 through 26 years. This report provides updated recommendations for routine and catch-up vaccination of females with either HPV2 or HPV4.

摘要

2009 年 10 月 16 日，美国食品和药物管理局（FDA）批准二价人乳头瘤病毒疫苗（HPV2；Cervarix，葛兰素史克）用于 10 至 25 岁女性。Cervarix 是美国批准用于女性的第二种人乳头瘤病毒（HPV）疫苗。四价 HPV 疫苗（HPV4；Gardasil，默克公司）于 2006 年获准用于 9 至 26 岁女性，免疫实践咨询委员会（ACIP）建议对 11 或 12 岁女性常规接种 HPV4 疫苗，并对 13 至 26 岁女性进行补种。本报告提供了更新的建议，用于常规和补种接种 HPV2 或 HPV4 的女性。